Branded drug: Concerta
U.S. sales: $1.23 billion
Attention-deficit hyperactivity disorder is one of the most frequently diagnosed neurological disorders and treating patients, mostly kids, with ADHD is big business. In the 12 months that ended June 30, Watson Pharmaceuticals ($WPI) sold nearly as much of generic Concerta as the $1.3 billion Johnson & Johnson ($JNJ) sold last year. The two struck a deal in which Watson could go to market in May 2011 if J&J supplied the drug through 2014. The deal was seen as a way to help ease the pain of sales lost to generic competition.
Johnson & Johnson continues to cut generics deals on Concerta. In September, it settled a patent lawsuit with Impax Laboratories ($IPXL) and Teva Pharmaceutical Industries ($TEVA), agreeing to give them the right to make a generic by July 14, 2013. It also settled a suit with Irish drugmaker Kudco Ireland allowing a generic of Concerta this year if it could get its drug approved by the FDA. The generic competition is hitting Johnson & Johnson pretty hard. Financial filings show that sales of Concerta were off nearly 20% in the first 6 months of this year.
More generics of J&J's ADHD med Concerta coming
J&J drug sales hold their own, thanks to foreign growth
Shire pits Vyvanse against Concerta in ADHD trials
Antipsychotics, ADHD meds fuel rising psych-drug use